|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined therapeutic targeted strategies are awaited in NRAS-mutated and KIT-altered melanoma and could provide additional benefit.
|
31833955 |
2020 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Similar results were obtained for TRB CDR3s and NRAS mutants in melanoma.
|
31740784 |
2020 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Intra-patient heterogeneity was detected in 13.3% of patients for both BRAF and NRAS genes and was not associated with clinico-pathological characteristics of melanomas or metastases.
|
31774543 |
2020 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, in a cohort of 79 BRAF/NRAS double wild type cutaneous melanoma and 17 mucosal melanoma KIT mutation was assessed by Sanger sequencing of exons 9,11,13,17 and 18.
|
31848942 |
2020 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings thus show a new pathway involved in NRAS-mutant melanoma resistance and provide new opportunities for novel therapeutic options.
|
31549767 |
2020 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our study aims to evaluate and review other studies that present the frequency of mutations of BRAF, NRAS, and KIT genes for different populations, and analyse correlation to their clinical-pathological characteristics and to the demographics of melanoma.
|
31274706 |
2020 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Melanoma onset and progression are associated with a high variety of activating mutations in the MAPK-pathway, most frequently involving BRAF (35-45%) and NRAS (15-25%) genes, but also c-KIT and PTEN.
|
31446019 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Both the melanomas harbor KIT mutation in approximately 15% of the cases; BRAF or NRAS mutation is found in approximately 10-15% of acral melanoma, but these mutations are less frequent in mucosal melanoma.
|
30675668 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Remarkably two-thirds of BRAF/NRAS wild-type melanomas harbor activating mutations or CNVs in receptor tyrosine kinases.
|
30561760 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Further leverage of the SPRY4 pathway may also hold therapeutic promise for NRAS(Q61) melanomas.
|
30651601 |
2019 |
|
melanoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.
|
29883661 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (<i>BRAF)</i> and neuroblastoma RAS viral oncogene homolog (<i>NRAS)</i> mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with <i>BRAF</i> and <i>NRAS</i> mutations.
|
31398831 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation.
|
31129802 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mutational status of NRAS is required in several types of cancer like colorectal or cutaneous melanoma.
|
29101736 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Disseminated intravascular coagulation and melanoma: a novel case occurring in metastatic melanoma with BRAF and NRAS mutations and systematic review.
|
31095038 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The neuroblastoma RAS viral oncogene homolog isoforms appear to play varying roles in melanoma phenotype and could potentially serve as biomarkers for therapeutic response and disease prognosis.
|
31116161 |
2019 |
|
melanoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, we developed ZT-12-037-01 (1a) as a specific STK19-targeted inhibitor and showed that it effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo.
|
30712867 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The activating NRAS p.Q61R variant is a known "hotspot" variant, frequently identified in several types of human cancer, especially melanoma.
|
30542204 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
|
31630873 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeted therapy may be useful for patients with CJM, especially those with activating BRAF mutations, whereas NRAS-mutated melanomas are relatively resistant.
|
31247083 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
|
30793515 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In LNs of melanoma patients, we detected the expression of melanoma-associated transcripts including MLANA (encoding for MelanA protein), analyzed the BRAF and NRAS mutational status and confirmed the malignant origin of isolated melanoma DCCs by comparative genomic hybridization.
|
30586191 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma.
|
30819666 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Sixty five consecutive formalin-fixed paraffin-embedded (FFPE) melanoma samples were prospectively tested for BRAF mutations with the VE1 (anti-BRAF V600E) antibody and for both BRAF and NRAS mutations with the Idylla NRAS-BRAF-EGFR S492R Mutation Assay cartridges.
|
31415669 |
2019 |
|
melanoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
|
30003571 |
2018 |